Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers
Conditions
Interventions
ALN-4285
Placebo
Locations
1
United Kingdom
Clinical Trial Site
London, United Kingdom
Start Date
December 12, 2025
Primary Completion Date
December 29, 2026
Completion Date
March 23, 2027
Last Updated
April 17, 2026
NCT00104325
NCT07118891
NCT01399385
NCT03807401
NCT07271693
NCT07499050
Lead Sponsor
Alnylam Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions